	US 12,016,951 B2
	Edaravone pharmaceutical composition
Yilong Wang, Beijing (CN); Yongjun Wang, Beijing (CN); Xingquan Zhao, Beijing (CN); and Anyuan Zhang, Nanjing (CN)
Assigned to BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY, Beijing (CN); and NANJING BAIXINYU PHARMACEUTICAL CO. LTD., Nanjing (CN)
Appl. No. 17/049,648
Filed by BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY, Beijing (CN); and NANJING BAIXINYU PHARMACEUTICAL CO. LTD., Nanjing (CN)
PCT Filed Dec. 27, 2018, PCT No. PCT/CN2018/124247 § 371(c)(1), (2) Date Oct. 22, 2020, PCT Pub. No. WO2019/205700, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 201810392676.8 (CN), filed on Apr. 27, 2018; and application No. 201810797624.9 (CN), filed on Jul. 19, 2018.
Prior Publication US 2021/0244657 A1, Aug. 12, 2021
Int. Cl. A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/4152 (2006.01)

CPC A61K 9/006 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 31/4152 (2013.01)]

20 Claims

1. A sublingual pharmaceutical composition comprising edaravone or a salt thereof as a sole active ingredient, a filler, a binder and a disintegrant;

wherein the filler comprises mannitol but not comprises lactose;

wherein the binder comprises hydroxypropyl methylcellulose but does not comprises copovidone; and

wherein the disintegrant comprises at least one agent selected from the group consisting of croscarmellose sodium and crospovidone.

10. A method of treating cerebrovascular disease or amyotrophic lateral sclerosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the sublingual pharmaceutical composition according to claim 1.